Fig. 6

The in vivo effects of elesclomol on tumor xenografts in mice. A Coronal sections of mouse brain through the tumor implanted in the cerebral hemisphere. Representative images of coronal mouse brain sections at 8 weeks after the intracranial injection of GSCs. The white dashed lines indicate the intracranial tumors identified by the presence of GFP+ cells. Scale bar: 200 μm. B Graph showing the tumor volume for the intracranial tumors after 8 weeks from the injection of GSCs. ** p < 0.01 (Student-t test). C Representative images of brain tissue of mice stained using Hoechst and an antibody specific for Ki67. Scale bar: 20 μm. A reduction in the number of dividing cells is observed following the different antitumoral treatments with a particular significant effect for the combination elesclomol + TMZ, as indicated in the corresponding graph. ** p < 0.01; *** p < 0.001 (Student-t test). D Representative images of brain sections stained using Hoechst and an antibody specific for GFAP, marker for reactive astrocytes. Elesclomol alone or in combination with TMZ induces a reduction in the expression of GFAP in the cells around and within the tumoral area. Astrocytes appear faintly stained and with a thin morphology as compared with control and TMZ treatment alone brain samples. Scale bar: 20 μm